PET-CT - Oncology Registry
National Oncologic PET Registry
The objective of the NOPR is to assess the effect of positron emission tomography with F-18 fluorodeoxyglucose (PET) on referring physicians' plans of intended patient management for those cancers and indications not currently eligible for reimbursement from the Centers for Medicare and Medicaid Services (see chart of eligible indications). Data will be collected from the referring physician before and after the PET study. If complete and timely data are reported to the NOPR within 30 days of the PET scan, the PET facility and interpreting physician will be eligible for reimbursement by CMS.
Collection of the information required by the NOPR is a condition for reimbursement of the PET scan by the Medicare program. (CMS has designated this mechanism for reimbursement as "coverage with evidence development.") Patients would otherwise be required to pay for the PET study themselves or be unable to have a PET scan performed at all.
For more information about this federal program see: http://www.cancerpetregistry.org/
More Medicare Patients can Benefit from the Advantages of a FDG PET-CT scan under New Federal Program
The National Oncologic PET Registry (NOPR) will soon mark its third year. Since the NOPR launched on May 8, 2006, data on more than 40,000 PET and PET-CT studies have been logged into the registry at nearly 1,300 locations throughout the United States.
UVa Department of Radiology is pleased to have participated with this study since it began. Changes are in the works with new forms and guidelines and the Medical Center is proud to continue its association with this valuable program. As soon as we have the information we will post it on this site. Thank you for your patience.
The NOPR was developed in response to the Centers for Medicare and Medicaid Services' (CMS') proposal to expand coverage for PET scans that are currently ineligible for Medicare reimbursement. (See chart of eligible indications) Because enrollment is open, patients can still receive this benefit. The results from the NOPR data analysis will help guide future CMS coverage decisions regarding coverage of FDG PET for conditions not currently covered.
Medicare reimbursement for these cancers will be available if the patient's referring physician submits data to a CMS-sponsored clinical registry to assess the impact of PET on cancer patient management. There is no charge to referring physicians or to patients for registry participation. UVA Department of Radiology will collect and submit all required forms to facilitate participation in the program.
This program offers a tremendous opportunity for demonstrating the role for PET in effective management of cancer patients. It is expected that the information gained will result in the expansion of PET covered indications once the program is concluded.
|Patient Eligibility for NOPR||Referring Physician's Responsibilities for NOPR|
|NOPR Patient Information Sheet||NOPR Physician Information sheet|
For any questions or concerns:
Contact the Radiology and Medical Imaging department at 434-924-9400.